• MEDIMABBIO

  • DISCOVER

    NEXT GENERATION IMMUNOTHERAPY
    FOR CANCER

  • 메인비주얼이미지

    MEDIMABBIO

  • 메인비주얼이미지
    DISCOVER

    NEXT GENERATION IMMUNOTHERAPY
    FOR CANCER

  • 메인비주얼이미지

    MEDIMABBIO

  • 메인비주얼이미지

    MEDIMABBIO

  • 메인비주얼이미지
    DISCOVER

    NEXT GENERATION IMMUNOTHERAPY
    FOR CANCER

SCROLL DOWN
About Us
about 이미지 about 이미지 about 이미지
MediMabBio is a ground-breaking biotherapeutic company focusing on the generation of novel immunotherapies
for the treatment of cancer.

Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumors.

The company has developed a pipeline of highly promising novel drugs that aims to overcome the current limitations of cancer immunotherapy.

For this purpose, MediMabBio has established collaborations with core partners of academic, R&D institutions and clinical groups in US, UK, Germany, China and Korea.

Pipeline
MMB pipeline addresses significant medically unmet needs in immuno-oncology by directly
targeting T cells, immune checkpoints and tumor micro-environment.
Category Program Therapeutic Indication Development stage
Target Discovery Hit Optimization Lead Optimization Pre-clinical IND Clinical
Immune Checkpoint Antibody MMB-101 Immuno Oncology
MMB-102 Immuno Oncology
MMB-103 Immuno Oncology
Immuno-cytokine MMB-201 Immuno Oncology
Program Therapeutic Indication Development stage
Discovery Development Pre-/Clinical
MMB-101 Immuno Oncology
MMB-102 Immuno Oncology
MMB-103 Immuno Oncology
MMB-201 Immuno Oncology
Program Development stage
Discovery Development Pre-/Clinical
MMB-101
MMB-102
MMB-103
MMB201
Management
  • 여자 여자 여자
    Jennifer Yuhoi Kang, Ph.D Founder & Co-CEO
    EXPERIENCE
    • Samsung Bioepis
    • Samsung Advanced Institute of Technology
    • Harvard Medical School
    • University of Oxford
    EDUCATION University of Oxford (Biochemistry Ph.D) EXPERTISE Oncology, Infectious disease, lmmuno-oncology
    therapy, Vaccine development
  • 여자 여자 여자
    Hongseok Jo, Ph.D Founder & Co-CEO
    EXPERIENCE
    • Samsung Bioepis
    • Samsung Advanced Institute of Technology
    • KAIST
    EDUCATION KAIST (Bioscience Ph.D) EXPERTISE Biologics drug discovery and development,
    Oncology, Neurological disorder